Revolutionising cell and gene therapy with polyNaut®

ViaNautis is transforming cell and gene therapy with polyNaut®, a versatile, non-viral, targeted polymer-based nanovesicles delivery system that enables precise, plug-and-play targeting to cells in the central nervous system, lung, and immune system.

Targeted polymer-based nanovesicle (tPNV)

With broad payload flexibility, good tolerability and simplified, scalable manufacturing, ViaNautis is making safe, shelf-stable and re-dosable genetic therapies accessible to patients.

Latest News & Events

ASGCT 2026: non-viral delivery under the spotlight

Post written by Adi Hoess, CEO Recently, Ray Jupp, CSO and I went to ASGCT’s 2026 annual meeting in Boston, which showcased a range of…

ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting

Press Releases

Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell‑specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are simple to…

ViaNautis Bio featured in Drug Discovery World articles

In The News

ViaNautis Bio has recently been featured in multiple articles in Drug Discovery World. Cell and gene therapies – looking forward Our Chief Business Officer, Sam…

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

Press Releases

Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types.

ViaNautis Appoints Ray Jupp as Chief Scientific Officer

Press Releases

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as…

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

Press Releases

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as…

View All News & Events